ArticleEuropean child & adolescent psychiatry2026
Age of onset: static and dynamic brain regional activity in first-episode drug-naïve schizophrenia.
Article in European child & adolescent psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe age at which schizophrenia manifests is a critical factor influencing long-term outcomes. It is essential to distinguish the effects of the illness phase from those of the age of onset. We assessed static/dynamic brain regional activity from 428 participants, split into four groups based on onset-age (early-onset schizophrenia [EOS] and adult-onset schizophrenia [AOS]) and treatment status: (1) drug-naïve first-episode patients (48 EOS and 62 AOS); (2) patients treated for ≤ 12 months (60 EOS and 53 AOS); (3) patients treated for > 12 months (56 EOS and 56 AOS); and (4) 93 healthy controls (32 age-matched with EOS, 61 age-matched with AOS). We conducted a principal component analysis and subsequent 2 × 2 factorial analysis on the extracted first component representing static/dynamic regional activity, followed by an out-of-sample imaging transcriptomics analysis. The stability of results from the drug-naïve groups were tested on the treated groups to account for antipsychotic effects. Onset-age had a notable interaction with diagnosis on the static activity of the thalamus, mid-cingulate cortex (MCC), cerebellum posterior lobe (CPL), precuneus, and putamen, and on the dynamic stability of the CPL, thalamus, and superior parietal lobule (SPL). Phase of illness and medication exposure did not affect the onset-age effect seen at the MCC, thalamus, and SPL. Transcriptomics analysis pointed to the possibility of a shared disruption in neuronal differentiation across the MCC, thalamus and SPL. Onset-age affects thalamo-fronto-parietal regional hemodynamic activity, possibly through disrupted neuronal differentiation, in schizophrenia. Exposure to antipsychotics do not reverse this functional imprint of the earlier illness onset, raising the question of alternate therapeutic approaches to close the observed "neurophysiological gap".
Indexed as
Identifiers
42142164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.